Navigation Links
Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006
Date:3/13/2008

cies regarding approval of our technology and products; the requirement for substantial funding to conduct research and development and to expand commercialization activities or consummate acquisitions; the accuracy of our estimations of the size of the market, and the potential market, for our products in specific disease areas; sales numbers and future guidance publicly provided by Boston Scientific Corporation regarding sales of their paclitaxel-eluting coronary stent products; and any other factors that may affect performance. In addition, our business is subject to certain operating risks that may cause the actual results expressed or implied by the forward-looking statements in this report to differ materially from our actual results. These operating risks include: our ability to attract and retain qualified personnel; our ability to successfully complete preclinical and clinical development of our products; changes in business strategy or development plans; our failure to obtain patent protection for discoveries; loss of patent protection resulting from third party challenges to our patents; commercialization limitations imposed by patents owned or controlled by third parties; our ability to obtain rights to technology from licensors; liability for patent claims and other claims asserted against us; our ability to obtain and enforce timely patent and other intellectual property protection for our technology and products; the ability to enter into, and to maintain, corporate alliances relating to the development and commercialization of our technology and products; market acceptance of our technology and products; our ability to successfully manufacture, market and sell our products; the ability of Boston Scientific Corporation to successfully manufacture, market and sell their paclitaxel-eluting coronary stent products; the continued availability of capital to finance our activities; our ability to achieve the financial benefits expected as a result of the ac
'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Angiotech and Rex Medical announce exclusive licensing and distribution agreement for the "Option(TM)" inferior vena cava filter
2. Angiotech showcases its Hemostream(TM) Dialysis Catheter at the Society of Interventional Radiology (SIR) Annual Meeting
3. Angiotech announces results for the fourth quarter ended December 31, 2007
4. Angiotech to participate in Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
5. Angiotech Pharmaceuticals, Inc. - Notice of Conference Call and Webcast
6. Angiotech and Symphony Medical Announce Licensing Agreement
7. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
8. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech to participate in Bank of America 2007 Credit Conference
11. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... yields to disease risks, the biological characteristics people care ... as for heightthe textbook example of a complex traitattributes ... by multiple genetic and environmental influences, making it challenging ... genes, geneticists typically mate two individuals that differ in ... mouseand then study their descendents, looking for genes that ...
(Date:9/19/2014)... Jose, California (PRWEB) September 19, 2014 ... Nanotechnology and its potential to revolutionize the world ... agencies, multinational corporations and small start-ups. The early ... funded research projects largely due to the high ... investments. Government budgets earmarked for this evolving technology ...
(Date:9/19/2014)... , Sept. 19, 2014  Nektar Therapeutics (NASDAQ: ... preclinical studies characterizing the analgesic profiles of a ... opioid receptor agonist molecules. The preclinical research candidates ... chemistry platform. The analgesic properties of ... medical literature. 1,2 Kappa opioid receptors are ...
(Date:9/19/2014)... Barnhardt Manufacturing Company has ... Organic Cotton . The USDA Certified Biobased Product ... ingredients meets or exceeds levels set by USDA. Biobased ... or in significant part of agricultural, forestry, or marine ... cotton to be immediately identified as a USDA certified ...
Breaking Biology Technology:Want to link genes to complex traits? Start with more diversity 2Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 2Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 3Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 5Barnhardt Manufacturing Company Earns USDA Certified Biobased Product Certification and Label for Organic Cotton 2
... , , ... As the study of protein biomarkers ... based on protein pathway information and discovery-based proteomics experiments. Even larger ... on microarray-based gene expression studies or other genomic information. , ...
... Purpose , ... and non-nucleoside reverse transcriptase inhibitor (NNRTI) antiretroviral drugs is of ... intra-individual metabolism variability. To be of practical use, it is ... is fast and easy to perform, with minimal sample preparation, ...
... Introduction , ... radioactively labeled using either endlabeled primers or by the ... results produced by these two labeling methods are highly ... or high secondary structure can cause DNA polymerases to ...
Cached Biology Technology:Multiplexed Quantitative Peptide Assays for Protein Biomarkers of Cardiovascular Disease in Human Plasma 2Multiplexed Quantitative Peptide Assays for Protein Biomarkers of Cardiovascular Disease in Human Plasma 3Multiplexed Quantitative Peptide Assays for Protein Biomarkers of Cardiovascular Disease in Human Plasma 4Multiplexed Quantitative Peptide Assays for Protein Biomarkers of Cardiovascular Disease in Human Plasma 5A simple and rapid LC-MS/MS method for the simultaneous determination of nine antiretroviral drugs commonly used in Europe (protease Inhibitors and non-nucleoside reverse transcriptase inhibitors) 2A simple and rapid LC-MS/MS method for the simultaneous determination of nine antiretroviral drugs commonly used in Europe (protease Inhibitors and non-nucleoside reverse transcriptase inhibitors) 3A simple and rapid LC-MS/MS method for the simultaneous determination of nine antiretroviral drugs commonly used in Europe (protease Inhibitors and non-nucleoside reverse transcriptase inhibitors) 4A simple method to sequence from bacterial colonies using [a-33P] radiolabeled ddNTPs and Thermo Sequenase 2A simple method to sequence from bacterial colonies using [a-33P] radiolabeled ddNTPs and Thermo Sequenase 3
(Date:9/18/2014)... Mass. A novel robotic system that can operate ... being tested as part of a biomedical research partnership ... the aim of determining if the robot, in conjunction ... faster, more accurate, less costly, and less discomforting for ... to deliver prostate cancer therapies with greater precision. , ...
(Date:9/18/2014)... a "frequent flyers" program, fruit flies surely would be ... hosted increasing numbers of fruit fly research studies. One ... April, and another is scheduled launch to the station ... in December. , Fruit flies are biomedical research models ... Model organisms can reveal the basis for health and ...
(Date:9/18/2014)... fall foliage season that prompts millions of Americans to undertake ... and possibly last a little longer within a century, according ... peeping in some areas of the United States as summer ... in the journal Global Ecology and Biogeography . For ... is the state tree of New Hampshire could change ...
Breaking Biology News(10 mins):Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 3Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 4Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 5Buzzing with activity: Fruit flies orbit Earth for science 2Buzzing with activity: Fruit flies orbit Earth for science 3Buzzing with activity: Fruit flies orbit Earth for science 4Fall foliage season may be later, but longer on warmer Earth 2Fall foliage season may be later, but longer on warmer Earth 3Fall foliage season may be later, but longer on warmer Earth 4
... 2010) Van Andel Research Institute (VARI) ... initiation and development of prostate cancer interact at the ... the disease. One of the proteins, androgen receptor, ... The other, steroid receptor coactivator-3 (SRC3), was originally ...
... S.C. As peach trees go, it doesn,t look much ... Research Farm, but appearances can be deceiving. This one, a ... a standout in the orchard. Its DNA its genetic ... scientists, enabling further research to identify beneficial traits to grow ...
... , This release is available in Spanish ... shoring up the defenses of U.S. varieties against Fusarium ... (FHB) disease. According to Agricultural Research Service (ARS) plant ... U.S. wheat varieties is primarily based on the Chinese wheat ...
Cached Biology News:VARI study could improve treatments for prostate cancer 2Researchers sequence DNA of peach tree at Clemson University 2Researchers sequence DNA of peach tree at Clemson University 3Diverse wheat tapped for antifungal genes 2
... is the first biological reagent ... them, and not just by ... only anti-mycoplasma agent that can ... stocks directly. The cytotoxicity of ...
... ester can be used to ... The covalently bound acridinium NHS ... the presence of hydrogen peroxide. ... be used as a detection ...
... assay (EMSA) is a powerful tool for ... gel shift or gel retardation, the assay ... subjected to electrophoresis, free DNA will migrate ... LightShift Chemiluminescent EMSA Kit is a nonradioactive ...
... 500 Series is a sophisticated ... most advanced technologies available. The ... testing, powerful software and a ... researchers optimize their overall workflow ...
Biology Products: